BIIB vs IQV
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BIIB shows neutral fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Mixed signals with both opportunities and risks present.
IQVIA exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a highly attractive PEG ratio of 0.68, suggesting significant undervaluation relative to its growth. While the stock is currently trading at a premium to its Graham Number ($82.24), it sits well below its intrinsic value ($231.28) and analyst targets ($231.60). However, the bullish fundamental outlook is contrasted by a severe technical downtrend and liquidity concerns, evidenced by a current ratio of 0.75 and high leverage. Overall, the company's robust ROE and consistent earnings growth make it a strong value play despite short-term price volatility.
Compare Another Pair
Related Comparisons
BIIB vs IQV: Head-to-Head Comparison
This page compares Biogen Inc. (BIIB) and IQVIA Holdings Inc. (IQV) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.